FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
NCT07216105
This study is recruiting at 5 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a Phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of FT836 with or without chemotherapy and/or trastuzumab or cetuximab, and to determine the recommended phase 2 dose (RP2D) of FT836 with or without chemotherapy and/or trastuzumab or cetuximab
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Non-Small Cell Lung Cancer
- Colorectal Cancer
- Breast Cancer
- Ovarian Cancer
- Endometrial Carcinoma
- Head and Neck Squamous Cell Carcinoma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Fate Therapeutics
- Last updated on ClinicalTrials.gov
- September 2, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- UC San Diego Moores Cancer Center · La Jolla, CA
- University of Southern California · Los Angeles, CA
Minnesota · 1
- University of Minnesota Masonic Cancer Center · Minneapolis, MN
Pennsylvania · 1
- Thomas Jefferson University, Sidney Kimmel Cancer Center · Philadelphia, PA
Texas · 1
- M. D. Anderson Cancer Center · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.